STUDIO MULTICENTRICO SULL'EFFICACIA DELLA LAMOTRIGINA: OSSERVAZIONI CLINICHE E METODOLOGICHE IN UN GRUPPO DI PAZIENTI

P. G. Zagnoni; S. Giubergia; G. Zaccara; G. C. Muscas; A. Tartara; R. Manni; C. M. Cornaggia; S. Gianetti; S. Binelli; G. Avanzini

STUDIO MULTICENTRICO SULL'EFFICACIA DELLA LAMOTRIGINA: OSSERVAZIONI CLINICHE E METODOLOGICHE IN UN GRUPPO DI PAZIENTI

Translated title of the contribution: Multicenter study on Lamotrigine efficacy: Clinical and methodological observations in a group of patients

P. G. Zagnoni, S. Giubergia, G. Zaccara, G. C. Muscas, A. Tartara, R. Manni, C. M. Cornaggia, S. Gianetti, S. Binelli, G. Avanzini

Research output: Contribution to journal › Article › peer-review

Abstract

We studied 41 patients suffering from pharmacoresistant focal epilepsy, medicated with PHT (22 patients) or CBZ (19 patients) to which LTG was gradually added. 25 patients dropped out during LTG add-on phase: 1 for withdrawal of consent, 5 for treatment failure, 4 for adverse events and 15 because the reduction of seizure number during PHT or CBZ withdrawal so they continued with LTG + PHT or LTG + CBZ. One of the patients died suddenly while on LTG + CBZ treatment. 10 patients completed the study reaching LTG monotherapy, of these 3 reached a complete seizure control, 4 had a seizure reduction higher than 50%, while 3 showed a seizure reduction between 6 and 36%. The LTG plasma concentration of the patients which completed the study with LTG monotherapy varied between 3,3 and 11,2 μg/ml (median 6,1) with a wide intraindividual variability notwithstanding the same LTG daily dose. The drawbacks of the study protocol are discussed as well as the problem of sudden unexplained death occurring in patients treated with LTG. These results should be confirmed by the final analysis of the international study owing to the limited sample of evaluated patients.

Translated title of the contribution	Multicenter study on Lamotrigine efficacy: Clinical and methodological observations in a group of patients
Original language	Italian
Pages (from-to)	135-137
Number of pages	3
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	86-87
Publication status	Published - 1994

ASJC Scopus subject areas

Clinical Neurology

Access to Document

Fingerprint Dive into the research topics of 'Multicenter study on Lamotrigine efficacy: Clinical and methodological observations in a group of patients'. Together they form a unique fingerprint.

Cite this

STUDIO MULTICENTRICO SULL'EFFICACIA DELLA LAMOTRIGINA : OSSERVAZIONI CLINICHE E METODOLOGICHE IN UN GRUPPO DI PAZIENTI. / Zagnoni, P. G.; Giubergia, S.; Zaccara, G.; Muscas, G. C.; Tartara, A.; Manni, R.; Cornaggia, C. M.; Gianetti, S.; Binelli, S.; Avanzini, G.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 86-87, 1994, p. 135-137.

Research output: Contribution to journal › Article › peer-review

@article{d1ca7d9c8ac340259176637efc48f23e,

title = "STUDIO MULTICENTRICO SULL'EFFICACIA DELLA LAMOTRIGINA: OSSERVAZIONI CLINICHE E METODOLOGICHE IN UN GRUPPO DI PAZIENTI",

abstract = "We studied 41 patients suffering from pharmacoresistant focal epilepsy, medicated with PHT (22 patients) or CBZ (19 patients) to which LTG was gradually added. 25 patients dropped out during LTG add-on phase: 1 for withdrawal of consent, 5 for treatment failure, 4 for adverse events and 15 because the reduction of seizure number during PHT or CBZ withdrawal so they continued with LTG + PHT or LTG + CBZ. One of the patients died suddenly while on LTG + CBZ treatment. 10 patients completed the study reaching LTG monotherapy, of these 3 reached a complete seizure control, 4 had a seizure reduction higher than 50%, while 3 showed a seizure reduction between 6 and 36%. The LTG plasma concentration of the patients which completed the study with LTG monotherapy varied between 3,3 and 11,2 μg/ml (median 6,1) with a wide intraindividual variability notwithstanding the same LTG daily dose. The drawbacks of the study protocol are discussed as well as the problem of sudden unexplained death occurring in patients treated with LTG. These results should be confirmed by the final analysis of the international study owing to the limited sample of evaluated patients.",

author = "Zagnoni, {P. G.} and S. Giubergia and G. Zaccara and Muscas, {G. C.} and A. Tartara and R. Manni and Cornaggia, {C. M.} and S. Gianetti and S. Binelli and G. Avanzini",

year = "1994",

language = "Italian",

pages = "135--137",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "86-87",

}

TY - JOUR

T1 - STUDIO MULTICENTRICO SULL'EFFICACIA DELLA LAMOTRIGINA

T2 - OSSERVAZIONI CLINICHE E METODOLOGICHE IN UN GRUPPO DI PAZIENTI

AU - Zagnoni, P. G.

AU - Giubergia, S.

AU - Zaccara, G.

AU - Muscas, G. C.

AU - Tartara, A.

AU - Manni, R.

AU - Cornaggia, C. M.

AU - Gianetti, S.

AU - Binelli, S.

AU - Avanzini, G.

PY - 1994

Y1 - 1994

N2 - We studied 41 patients suffering from pharmacoresistant focal epilepsy, medicated with PHT (22 patients) or CBZ (19 patients) to which LTG was gradually added. 25 patients dropped out during LTG add-on phase: 1 for withdrawal of consent, 5 for treatment failure, 4 for adverse events and 15 because the reduction of seizure number during PHT or CBZ withdrawal so they continued with LTG + PHT or LTG + CBZ. One of the patients died suddenly while on LTG + CBZ treatment. 10 patients completed the study reaching LTG monotherapy, of these 3 reached a complete seizure control, 4 had a seizure reduction higher than 50%, while 3 showed a seizure reduction between 6 and 36%. The LTG plasma concentration of the patients which completed the study with LTG monotherapy varied between 3,3 and 11,2 μg/ml (median 6,1) with a wide intraindividual variability notwithstanding the same LTG daily dose. The drawbacks of the study protocol are discussed as well as the problem of sudden unexplained death occurring in patients treated with LTG. These results should be confirmed by the final analysis of the international study owing to the limited sample of evaluated patients.

AB - We studied 41 patients suffering from pharmacoresistant focal epilepsy, medicated with PHT (22 patients) or CBZ (19 patients) to which LTG was gradually added. 25 patients dropped out during LTG add-on phase: 1 for withdrawal of consent, 5 for treatment failure, 4 for adverse events and 15 because the reduction of seizure number during PHT or CBZ withdrawal so they continued with LTG + PHT or LTG + CBZ. One of the patients died suddenly while on LTG + CBZ treatment. 10 patients completed the study reaching LTG monotherapy, of these 3 reached a complete seizure control, 4 had a seizure reduction higher than 50%, while 3 showed a seizure reduction between 6 and 36%. The LTG plasma concentration of the patients which completed the study with LTG monotherapy varied between 3,3 and 11,2 μg/ml (median 6,1) with a wide intraindividual variability notwithstanding the same LTG daily dose. The drawbacks of the study protocol are discussed as well as the problem of sudden unexplained death occurring in patients treated with LTG. These results should be confirmed by the final analysis of the international study owing to the limited sample of evaluated patients.

UR - http://www.scopus.com/inward/record.url?scp=0028674550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028674550&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0028674550

SP - 135

EP - 137

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 86-87

ER -